Literature DB >> 1645772

Tumor cell invasion inhibited by TIMP-2.

A Albini1, A Melchiori, L Santi, L A Liotta, P D Brown, W G Stetler-Stevenson.   

Abstract

The 72-kd type IV collagenase is a member of the collagenase enzyme family that has been closely linked with the invasive phenotype of cancer cells. Previous studies have shown that both normal cells and highly invasive tumor cells produce the 72-kd type IV procollagenase enzyme in a complexed form consisting of the proenzyme and a novel tissue inhibitor of metalloproteinases, TIMP-2. The balance between activated enzyme and available inhibitor is thought to be a critical determinant of the matrix proteolysis associated with a variety of pathologic processes, including tumor cell invasion. In the present study, we demonstrate that alteration of the metalloproteinase-metalloproteinase-inhibitor balance in favor of excess inhibitor blocks human fibrosarcoma HT-1080 tumor cell invasion of a reconstituted basement membrane. The HT-1080 cell line produces both the 72-kd and the 92-kd type IV collagenases. Alteration of the type IV collagenase-inhibitor balance was achieved by addition of free TIMP-2 or antibodies to 72-kd type IV collagenase. Native, purified TIMP-2 was inhibitory in the range of 1-25 micrograms/mL. Addition of specific antiserum against the 72-kd type IV collagenase, which did not cross-react with the 92-kd type IV collagenase, inhibited HT-1080 cell invasion to the same extent. These results suggest that metalloproteinases, in particular the 72-kd type IV collagenase, are critical for tumor cell invasion of the reconstituted basement membrane. Our findings demonstrate that addition of the endogenous inhibitor TIMP-2 is able to block invasion. Thus, we recommend initiation of in vivo studies of the therapeutic potential of TIMP-2 to block tumor cell invasion and intravasation into the circulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645772     DOI: 10.1093/jnci/83.11.775

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  71 in total

1.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis.

Authors:  L Guedez; A J McMarlin; D W Kingma; T A Bennett; M Stetler-Stevenson; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

3.  Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.

Authors:  Dimitra Bourboulia; Sandra Jensen-Taubman; Matthew R Rittler; Hui Ying Han; Tania Chatterjee; Beiyang Wei; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2011-09-18       Impact factor: 4.307

4.  Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma.

Authors:  Y Kitadai; L M Ellis; S L Tucker; G F Greene; C D Bucana; K R Cleary; Y Takahashi; E Tahara; I J Fidler
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases.

Authors:  A Matsuzaki; A Janowska-Wieczorek
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin.

Authors:  J J van den Oord; L Paemen; G Opdenakker; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

Review 7.  The matrix metalloproteinases and their inhibitors in pancreatic cancer. From molecular science to a clinical application.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1997-02

Review 8.  Tumoral invasion in the central nervous system.

Authors:  Y A De Clerck; H Shimada; I Gonzalez-Gomez; C Raffel
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction.

Authors:  Nawar A Alkhamesi; Gretta Roberts; Paul Ziprin; David H Peck
Journal:  Biomark Insights       Date:  2007-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.